Trial Profile
A Phase II Study of Pre-operative Panitumumab, Paclitaxel, Carboplatin and Continuous Infusion 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Dec 2012
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Fluorouracil (Primary) ; Paclitaxel (Primary) ; Panitumumab (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 27 Mar 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 04 Jan 2012 Actual patient number is 1 according to ClinicalTrials.gov.
- 04 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.